Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG lifted its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 46.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,206 shares of the biopharmaceutical company’s stock after buying an additional 2,616 shares during the period. Deutsche Bank AG owned about 0.07% of Corbus Pharmaceuticals worth $97,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its position in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 2,195 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the 4th quarter worth approximately $101,000. BNP Paribas Financial Markets acquired a new position in shares of Corbus Pharmaceuticals in the 4th quarter worth approximately $323,000. Jump Financial LLC acquired a new position in shares of Corbus Pharmaceuticals in the 4th quarter worth approximately $339,000. Finally, Bank of America Corp DE lifted its holdings in Corbus Pharmaceuticals by 29.7% during the 4th quarter. Bank of America Corp DE now owns 31,475 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 7,207 shares in the last quarter. Institutional investors and hedge funds own 64.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. HC Wainwright dropped their target price on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. B. Riley reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, May 7th. William Blair began coverage on shares of Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $50.88.

Corbus Pharmaceuticals Trading Up 13.1%

NASDAQ CRBP opened at $8.30 on Wednesday. Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $4.64 and a 1-year high of $61.90. The company has a 50 day moving average of $6.67 and a 200-day moving average of $9.62. The company has a market cap of $101.57 million, a price-to-earnings ratio of -1.77 and a beta of 3.19.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.13). On average, equities research analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 earnings per share for the current year.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.